ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 149.45

Change

-4.94 (-3.20)%

Market Cap

USD 3.92B

Volume

0.67M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B
INCY Incyte Corporation

+0.50 (+0.98%)

USD 12.79B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
GERM ETFMG Treatments Testing .. 6.36 % 0.00 %

+0.43 (+1.26%)

USD 0.01B
CURE:XETRA VanEck Genomics and Healt.. 3.60 % 0.00 %

+0.24 (+1.26%)

USD 6.89M
BTEC:SW iShares Nasdaq US Biotech.. 2.05 % 0.00 %

+0.07 (+1.26%)

USD 0.46B
IBBQ Invesco Nasdaq Biotechnol.. 2.05 % 0.00 %

+0.18 (+1.26%)

USD 0.03B
BIB ProShares Ultra Nasdaq Bi.. 1.46 % 0.95 %

+0.72 (+1.26%)

USD 0.10B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+0.70 (+1.26%)

USD 0.04B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+1.26%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+1.26%)

USD 0.49B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+1.26%)

USD 0.49B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

+0.08 (+1.26%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.08 (+1.26%)

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.00 % 0.00 %

+0.22 (+1.26%)

USD 4.28M
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.39 (+1.26%)

USD 3.51M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.92% 22% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.92% 22% F 18% F
Trailing 12 Months  
Capital Gain -23.41% 42% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.41% 42% F 29% F
Trailing 5 Years  
Capital Gain 59.93% 79% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.93% 79% B- 73% C
Average Annual (5 Year Horizon)  
Capital Gain 23.41% 75% C 83% B
Dividend Return 23.41% 75% C 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.88% 76% C+ 55% F
Risk Adjusted Return 69.07% 98% N/A 91% A-
Market Capitalization 3.92B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 184.06 1% 2%
Price/Free Cash Flow Ratio -85.03 99% 97%
Management Effectiveness  
Return on Equity -1,500.66% 4% 2%
Return on Invested Capital -34.83% 70% 28%
Return on Assets -4.78% 94% 40%
Debt to Equity Ratio -462.63% 96% 97%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.